Esperion Therapeutics (ESPR) Cash & Equivalents (2012 - 2026)

Esperion Therapeutics' Cash & Equivalents history runs 15 years deep, the most recent figure standing at $156.2 million for Q1 2026.

• Quarterly Cash & Equivalents rose 36.22% year-over-year to $156.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $156.2 million (up 36.22% YoY) and the FY2025 annual result came in at $167.9 million, up 15.95% from the prior year.
• Cash & Equivalents was $156.2 million for Q1 2026 at Esperion Therapeutics, down from $167.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $226.6 million in Q1 2024 and bottomed at $82.2 million in Q4 2023.
• A 5-year average of $138.9 million and a median of $144.7 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents soared 76.01% — and 2025, when it tumbled 54.54%.
• Esperion Therapeutics' Cash & Equivalents stood at $124.8 million in 2022, then sank by 34.08% to $82.2 million in 2023, then surged by 76.01% to $144.8 million in 2024, then gained by 15.95% to $167.9 million in 2025, then declined by 6.97% to $156.2 million in 2026.
• Business Quant data shows ESPR's Cash & Equivalents at $156.2 million in Q1 2026, $167.9 million in Q4 2025, and $92.4 million in Q3 2025.